Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), is a biopharmaceutical company, which mainly focuses on global immunology, today announced the successful results of Voclosporin, in the treatment of Japanese patients.
The successful results pertained from the Phase I studies of this treatment process, indicate a strong evaluation, that the company will proceed to strengthen the development of their drug, in this specific region.
What the Japanese Phase I Results Indicated On Behalf of Voclosporin
According to those familiar with the matter, as well as the results, which were released regarding the Phase I trial, it was seen that the drug was more or less consistent with the patients it was administered to, regardless of the demographics, of said patients.
Furthermore, throughout the study, another bold stroke of fortune for the drug, is that there were no unexpected incidents, regarding adverse side-effects, or unexpected safety signals, this all leads to a positive outcome in the trial for the drug.
Comments from the company regarding Voclosporin
The company released a statement, in which they explained that they were relieved that the treatment efficiency of the drug was universal, amongst different ethnic groups. In the same statement, the company explained, that this is merely the first step of the drug.
According to the statements made, the company intends to further test and develop the drug, through implementing Phase III trials in both Japanese, as well as non-Japanese patients. The company did state that they would be sharing the results of this trial, with both Japanese Pharmaceuticals, as well as Medical Device Agency (FDMA), at the end Q2.
The CEO of Aurinia, Richard Glickman, stated, “Japan represents an important market opportunity for Voclosporin to treat patients with active nephritis. The results of this study will support our upcoming discussions with Japanese regulatory authorities and potential partners as we continue our efforts to bring this important therapy to patients around the globe.”